Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

키워드

참고문헌 (190)

1. 이유경, "Developing a Scoring Guide for the Appraisal of Guidelines for Research and Evaluation II Instrument in Korea: A Modified Delphi Consensus Process", Journal of Korean Medical Science, 28(2), pp.190~194 (2013), 대한의학회
2. "Clinical spectrum of SARS-CoV-2 infection"[URL]
3. Guyatt G, "GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes", J Clin Epidemiol, 66, pp.151~157 (2013)
4. "GRADE handbook"[URL]
5. Brown AJ, "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase", Antiviral Res, 169, pp.104541~ (2019)
6. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci Transl Med, 9 (2017)
7. Sheahan TP, "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV", Nat Commun, 11, pp.222~ (2020)
8. Dörnemann J, "First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease", J Infect Dis, 215, pp.171~174 (2017)
9. Mulangu S, "A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics", N Engl J Med, 381, pp.2293~2303 (2019)
10. Beigel JH, "ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report", N Engl J Med, 383, pp.1813~1826 (2020)
11. WHO Solidarity Trial Consortium, "Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results", N Engl J Med, 384, pp.497~511 (2021)
12. "Therapeutics and COVID-19: living guideline"[URL]
13. Wang Y, "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
14. Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial", JAMA, 324, pp.1048~1057 (2020)
15. Joo Eun-Jeong, "Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study", Journal of Korean Medical Science, 36(11), pp.1~13 (2021), 대한의학회[DOI]
16. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virol J, 2, pp.69~ (2005)
17. Keyaerts E, "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine", Biochem Biophys Res Commun, 323, pp.264~268 (2004)
18. Barnard DL, "Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB", c mice, 2006, pp.17, 275~284
19. Biot C, "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities", J Med Chem, 49, pp.2845~2849 (2006)
20. McChesney EW, "Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate", Am J Med, 75, pp.11~18 (1983)
21. Liu J, "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro", Cell Discov, 6, pp.16~ (2020)
22. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", Clin Infect Dis, 71, pp.732~739 (2020)
23. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
24. Weniger H, "Review of side effects and toxicity of chloroquine" (1979), WHO
25. Danesi R, "Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg", J Antimicrob Chemother, 51, pp.939~945 (2003)
26. Tran DH, "Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process", J Antibiot (Tokyo), 72, pp.759~768 (2019)
27. Iannetta M, "Azithromycin shows anti-Zika virus activity in human glial cells", Antimicrob Agents Chemother, 61, pp.e01152~e01117 (2017)
28. Li C, "Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses", Antimicrob Agents Chemother, 63, pp.E00394~E00319 (2019)
29. RECOVERY Collaborative Group, "Effect of hydroxychloroquine in hospitalized patients with Covid-19", N Engl J Med, 383, pp.2030~2040 (2020)
30. Andreani J, "In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2shows synergistic effect", Microb Pathog, 145, pp.104228~ (2020)
31. Kanoh S, "Mechanisms of action and clinical application of macrolides as immunomodulatory medications", Clin Microbiol Rev, 23, pp.590~615 (2010)
32. Rosenberg ES, "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state", JAMA, 323, pp.2493~2502 (2020)
33. Parnham MJ, "Azithromycin:mechanisms of action and their relevance for clinical applications", Pharmacol Ther, 143, pp.225~245 (2014)
34. Gautret P, "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study", Travel Med Infect Dis, 34, pp.101663~ (2020)
35. Bonny A, "Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”", Travel Med Infect Dis, 37, pp.101861~ (2020)
36. Molina JM, "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection", Med Mal Infect, 50, pp.384~ (2020)
37. Guérin V, "Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild", moderate COVID-19, 2020, pp.18, 45~55
38. "Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine"[URL]
39. Risch HA, "Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped-up immediately as key to the pandemic crisis", Am J Epidemiol, 189, pp.1218~1226 (2020)
40. Mahévas M, "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data", BMJ, 369, pp.m1844~ (2020)
41. Magagnoli J, "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19", Med (N Y), 1, pp.114~127.e3 (2020)
42. Geleris J, "Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19", N Engl J Med, 382, pp.2411~2418 (2020)
43. Arshad S, "Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19", Int J Infect Dis, 97, pp.396~403 (2020)
44. Cavalcanti AB, "Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19", N Engl J Med, 383, pp.2041~2052 (2020)
45. Self WH, "Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial", JAMA, 324, pp.2165~2176 (2020)
46. Ulrich RJ, "Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients", Open Forum Infect Dis, 7 (2020)
47. Abd-Elsalam S, "Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study", Am J Trop Med Hyg, 103, pp.1635~1639 (2020)
48. Chen J, "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19", Zhejiang Da Xue Xue Bao Yi Xue Ban, 49, pp.215~219 (2020)
49. Lyngbakken MN, "A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics", Nat Commun, 11, pp.5284~ (2020)
50. Tang W, "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial", BMJ, 369 (2020)
51. Chen L, "Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study" (2020)
52. Mitjà O, "Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial", Clin Infect Dis (2020)
53. Skipper CP, "Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized Trial", Ann Intern Med, 173, pp.623~631 (2020)
54. Chen CP, "A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)", PLoS One, 15, pp.e0242763~ (2020)
55. Mikami T, "Risk factors for mortality in patients with COVID-19 in New York city", J Gen Intern Med, 36, pp.17~26 (2021)
56. Catteau L, "Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants", Int J Antimicrob Agents, 56, pp.106144~ (2020)
57. The COVID-19 RISK and Treatments (CORIST) Collaboration, "Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study", Eur J Intern Med, 82, pp.38~47 (2020)
58. Yu B, "Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19", Sci China Life Sci, 63, pp.1515~1521 (2020)
59. Szente Fonseca SN, "Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis", Travel Med Infect Dis, 38, pp.101906~ (2020)
60. Huang HD, "Safety and effectiveness of hydroxychloroquine and azithromycin combination therapy for treatment of hospitalized patients with COVID-19: a propensity-matched study", Cardiol Ther, 9, pp.523~534 (2020)
61. Annie FH, "Hydroxychloroquine in hospitalized patients with COVID-19: real-world experience assessing mortality", Pharmacotherapy, 4, pp.1072~1081 (2020)
62. Kalligeros M, "Hydroxychloroquine use in hospitalised patients with COVID-19: an observational matched cohort study", J Glob Antimicrob Resist, 22, pp.842~844 (2020)
63. Paccoud O, "Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital", Clin Infect Dis (2020)
64. Satlin MJ, "Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease", PLoS One, 15, pp.e0236778~ (2020)
65. Furtado RHM, "Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial", Lancet, 396, pp.959~967 (2020)
66. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial", Int J Antimicrob Agents, 56, pp.105949~ (2020)
67. Faíco-Filho KS, "No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19", Braz J Microbiol, 51, pp.1765~1769 (2020)
68. Karolyi M, "Hydroxychloroquine versus lopinavir", ritonavir in severe COVID-19 patients : Results from a real-life patient cohort, 2020, pp.2020, 1~8
69. Ji-Won Kim, "Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019", The Korean Journal of Internal Medicine, 36, pp.253~263 (2021), 대한내과학회[DOI]
70. Lecronier M, "Comparison of hydroxychloroquine, lopinavir", ritonavir, and standard of care in critically ill patients with SARS-CoV-2pneumonia: an opportunistic retrospective analysis, 2020, pp.24, 418~
71. Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir: a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
72. Choy KT, "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2replication in vitro", Antiviral Res, 178, pp.104786~ (2020)
73. RECOVERY Collaborative Group, "Lopinavir-ritonavir in patients admitted to hospital with COVID-19(RECOVERY): a randomised, controlled, open-label, platform trial", Lancet, 396, pp.1345~1352 (2020)
74. Cao B, "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
75. Li Y, "Efficacy and Safety of Lopinavir", Ritonavir or Arbidol in Adult Patients with Mild, Med (N Y), pp.2020, 1[DOI]
76. Arshad U, "Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics", Clin Pharmacol Ther, 108, pp.775~790 (2020)
77. Shiraki K, "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections", Pharmacol Ther, 209, pp.107512~ (2020)
78. Furuta Y, "Favipiravir (T-705), a novel viral RNA polymerase inhibitor", Antiviral Res, 100, pp.446~454 (2013)
79. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", Cell Res, 30, pp.269~271 (2020)
80. Ströher U, "Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha", J Infect Dis, 189, pp.1164~1167 (2004)
81. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS: initial virological and clinical findings, 2004, pp.59, 252~256
82. Tan EL, "Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs", Emerg Infect Dis, 10, pp.581~586 (2004)
83. Chan JF, "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus", J Infect, 67, pp.606~616 (2013)
84. Stockman LJ, "SARS: systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
85. Chen F, "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds", J Clin Virol, 31, pp.69~75 (2004)
86. Morgenstern B, "Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines", Biochem Biophys Res Commun, 326, pp.905~908 (2005)
87. Blaising J, "Arbidol as a broad-spectrum antiviral: an update", Antiviral Res, 107, pp.84~94 (2014)
88. Wang X, "The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro", Cell Discov, 6, pp.28~ (2020)
89. Shirley M, "Baloxavir marboxil: a review in acute uncomplicated influenza", Drugs, 80, pp.1109~1118 (2020)
90. Lou Y, "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial", Eur J Pharm Sci, 157, pp.105631~ (2021)
91. Chen C, "Favipiravir versus arbidol for COVID-19: a randomized clinical trial" (2020)
92. Ivashchenko AA, "AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II", III multicenter randomized clinical trial, 2020, ~
93. Doi Y, "A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19", Antimicrob Agents Chemother, 64, pp.e01897~e01820 (2020)
94. Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study", Engineering (Beijing), 6, pp.1192~1198 (2020)
95. Kocayiğit H, "Observational study of the effects of favipiravir vs lopinavir", ritonavir on clinical outcomes in critically Ill patients with COVID-19, 2021, pp.46, 454~459
96. Yethindra V, "Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients", Int J Pharm Sci Res, 11, pp.506~509 (2020)
97. Zhu Z, "Arbidol monotherapy is superior to lopinavir", ritonavir in treating COVID-19, 2020, pp.81, e21~e23
98. Deng L, "Arbidol combined with LPV", r versus LPV, J Infect, pp.2020, 81[DOI]
99. Lian N, "Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study", Clin Microbiol Infect, 26, pp.917~921 (2020)
100. Fang J, "Efficacy of early combination therapy with lianhuaqingwen and arbidol in moderate and severe COVID-19 patients: a retrospective cohort study", Front Pharmacol, 11, pp.560209~ (2020)
101. Chen W, "A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19", J Med Virol, 92, pp.2702~2708 (2020)
102. Gao W, "Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series", Virol J, 17, pp.162~ (2020)
103. Hung IF, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
104. . Huang YQ, "No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir", ritonavir plus interferon-alpha, and ribavirin plus lopinavir, Front Pharmacol, pp.2020, 11[DOI]
105. Abbaspour Kasgari H, "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial", J Antimicrob Chemother, 75, pp.3373~3378 (2020)
106. Yuan J, "The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients", Inflamm Res, 69, pp.599~606 (2020)
107. Tong S, "Ribavirin therapy for severe COVID-19: a retrospective cohort study", Int J Antimicrob Agents, 56, pp.106114~ (2020)
108. Eslami G, "The impact of sofosbuvir", daclatasvir or ribavirin in patients with severe COVID-19, 2020, pp.75, 3366~3372
109. Lund LH, "The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time", J Heart Lung Transplant, 36, pp.1037~1046 (2017)
110. Franchimont D, "Glucocorticoids and inflammation revisited:the state of the art. NIH clinical staff conference", Neuroimmunomodulation, 10, pp.247~260 (2003)
111. Krafft P, "The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations", Intensive Care Med, 22, pp.519~529 (1996)
112. Meduri GU, "Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome", Chest, 108, pp.1303~1314 (1995)
113. Meduri GU, "Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time", Chest, 107, pp.1062~1073 (1995)
114. Chrousos GP, "The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation", N Engl J Med, 332, pp.1351~1362 (1995)
115. Arabi YM, "Saudi critical care trial group. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome", Am J Respir Crit Care Med, 197, pp.757~767 (2018)
116. Rochwerg B, "Corticosteroids in sepsis: an updated systematic review and meta-analysis", Crit Care Med, 46, pp.1411~1420 (2018)
117. Lian XJ, "Reevaluating the role of corticosteroids in septic shock: an updated meta-analysis of randomized controlled trials", BioMed Res Int, 2019, pp.3175047~ (2019)
118. Villar J, "Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial", Lancet Respir Med, 8, pp.267~276 (2020)
119. Lewis SR, "Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome", Cochrane Database Syst Rev, 7, pp.CD004477~ (2019)
120. ECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
121. Tomazini BM, "Effect of dexamethasone on days alive and ventilatorfree in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial", JAMA, 324, pp.1307~1316 (2020)
122. Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients With COVID-19: a randomized clinical trial", JAMA, 324, pp.1298~1306 (2020)
123. "Errors", ~
124. Jeronimo CMP, "Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial", Clin Infect Dis (2020)
125. Ruiz-Irastorza G, "Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data", PLoS One, 15, pp.e0239401~ (2020)
126. Majmundar M, "Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region", PLoS One, 15, pp.e0238827~ (2020)
127. Bartoletti M, "Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study", Clin Microbiol Infect, 27, pp.105~111 (2021)
128. Li Q, "Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study", Infect Dis Ther, 9, pp.823~836 (2020)
129. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis", JAMA, 324, pp.1330~1341 (2020)
130. World Health Organization (WHO), "Clinical management of severe acute respiratory infection (SARI)when COVID-19 disease is suspected: interim guidance, 13 March 2020" (2020), WHO
131. Lamontagne F, "Corticosteroid therapy for sepsis: a clinical practice guideline", BMJ, 362, pp.k3284~ (2018)
132. Akira S, "Interleukin-6 in biology and medicine", Adv Immunol, 54, pp.1~78 (1993)
133. Choy EH, "Translating IL-6 biology into effective treatments", Nat Rev Rheumatol, 16, pp.335~345 (2020)
134. Zhang C, "Cytokine release syndrome in severe COVID-19: interleukin-6receptor antagonist tocilizumab may be the key to reduce mortality", Int J Antimicrob Agents, 55, pp.105954~ (2020)
135. McGonagle D, "The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease", Autoimmun Rev, 19, pp.102537~ (2020)
136. Coomes EA, "Interleukin-6 in Covid-19: a systematic review and meta-analysis", Rev Med Virol, 30, pp.1~9 (2020)
137. Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China", Intensive Care Med, 46, pp.846~848 (2020)
138. Qin C, "Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China", Clin Infect Dis, 71, pp.762~768 (2020)
139. Gupta S, "Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19", JAMA Intern Med, 181, pp.41~51 (2021)
140. Sciascia S, "Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19", Clin Exp Rheumatol, 38, pp.529~532 (2020)
141. De Rossi N, "Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up", EClinicalMedicine, 25, pp.100459~ (2020)
142. Campochiaro C, "Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study", Eur J Intern Med, 76, pp.43~49 (2020)
143. Kewan T, "Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study", EClinicalMedicine, 24, pp.100418~ (2020)
144. Guaraldi G, "Tocilizumab in patients with severe COVID-19: a retrospective cohort study", Lancet Rheumatol, 2, pp.e474~e484 (2020)
145. Rodríguez-Baño J, "Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)", Clin Microbiol Infect, 27, pp.244~252 (2021)
146. Biran N, "Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study", Lancet Rheumatol, 2, pp.e603~e612 (2020)
147. Chilimuri S, "Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study", J Clin Pharm Ther, 46, pp.440~446 (2021)
148. Stone JH, "Efficacy of tocilizumab in patients hospitalized with Covid-19", N Engl J Med, 383, pp.2333~2344 (2020)
149. Rosas IO, "Tocilizumab in hospitalized patients with severe Covid-19 pneumonia", N Engl J Med (2021)
150. "Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia"[URL]
151. Salvarani C, "Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial", JAMA Intern Med, 181, pp.24~31 (2021)
152. Hermine O, "Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial", JAMA Intern Med, 181, pp.32~40 (2021)
153. Wang D, "Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial", Front Med (2021)
154. Martínez-Sanz J, "Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study", Clin Microbiol Infect, 27, pp.238~243 (2021)
155. Boregowda U, "Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis", Front Med (Lausanne), 7, pp.586221~ (2020)
156. Aziz M, "Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis", J Med Virol, 93, pp.1620~1630 (2021)
157. Berardicurti O, "Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis", Clin Exp Rheumatol, 38, pp.1247~1254 (2020)
158. Kotak S, "Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence", Cureus, 12, pp.e10869~ (2020)
159. Lan SH, "Tocilizumab for severe COVID-19: a systematic review and meta-analysis", Int J Antimicrob Agents, 56, pp.106103~ (2020)
160. Tleyjeh IM, "Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis", Clin Microbiol Infect, 27, pp.215~227 (2021)
161. Montesarchio V, "Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy", J Immunother Cancer, 8, pp.e001089~ (2020)
162. Campbell L, "Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials", Rheumatology (Oxford), 50, pp.552~562 (2011)
163. Ingraham NE, "Immunomodulation in COVID-19", Lancet Respir Med, 8, pp.544~546 (2020)
164. Cavalli G, "Interleukin-1 blockade with highdose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study", Lancet Rheumatol, 2, pp.e325~e331 (2020)
165. Huet T, "Anakinra for severe forms of COVID-19: a cohort study", Lancet Rheumatol, 2, pp.e393~e400 (2020)
166. Langer-Gould A, "Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab", Int J Infect Dis, 99, pp.291~297 (2020)
167. Cauchois R, "Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19", Proc Natl Acad Sci U S A, 117, pp.18951~18953 (2020)
168. Narain S, "Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm", Chest, 159, pp.933~948 (2021)
169. Clementi N, "Interferon-β-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection", J Infect Dis, 222, pp.722~725 (2020)
170. Bastard P, "Autoantibodies against type I IFNs in patients with life-threatening COVID-19", Science, 370, pp.eabd4585~ (2020)
171. Zhang Q, "Inborn errors of type I IFN immunity in patients with life-threatening COVID-19", Science, 370, pp.eabd4570~ (2020)
172. "Interferon alpha-2b (Intron® A)"[URL]
173. Davoudi-Monfared E, "A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19", Antimicrob Agents Chemother, 64, pp.e01061~e01020 (2020)
174. "Ongoing clinical trials for interferon and COVI-19"[URL]
175. "Interferon alpha-2b (Intron® A)"[URL]
176. Monk PD, "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Respir Med, 9, pp.196~206 (2021)
177. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46
178. Mo Y, "A review of treatment modalities for Middle East respiratory syndrome", J Antimicrob Chemother, 71, pp.3340~3350 (2016)
179. Sahr F, "Evaluation of convalescent whole blood for treating ebola virus disease in freetown, Sierra Leone", J Infect, 74, pp.302~309 (2017)
180. Li L, "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial", JAMA, 324, pp.460~470 (2020)
181. Agarwal A, "Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)", BMJ, 371, pp.m3939~ (2020)
182. Avendaño-Solà C, "Convalescent plasma for COVID-19: a multicenter, randomized clinical trial"
183. "2020", ~
184. Simonovich VA, "A randomized trial of convalescent plasma in Covid-19 severe pneumonia", N Engl J Med, 384, pp.619~629 (2021)
185. Joyner MJ, "Safety update: COVID-19convalescent plasma in 20,000 hospitalized patients", Mayo Clin Proc, 95, pp.1888~1897 (2020)
186. 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
187. Gharebaghi N, "Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial", BMC Infect Dis, 20, pp.895~ (2020)
188. Sakoulas G, "Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19pneumonia: a prospective randomized trial" (2020)
189. Shao Z, "Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study", Clin Transl Immunology, 9, pp.e1192~ (2020)
190. Guo Y, "Adverse effects of immunoglobulin therapy", Front Immunol, 9, pp.1299~ (2018)

관련 논문AI추천